Persistence with cholinesterase inhibitor treatment in alzheimer's disease

Canadian Journal of Neurological Sciences

Volumn 40, Issue 5, 2013, Pages 623-624

  Massoud, Fadi ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; MEMANTINE; RIVASTIGMINE;

ALZHEIMER DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDITORIAL; FOLLOW UP; GENERAL CONDITION DETERIORATION; HUMAN; MINI MENTAL STATE EXAMINATION; PALLIATIVE THERAPY; PRESCRIPTION; PRIORITY JOURNAL; REIMBURSEMENT; SOCIOECONOMICS; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

EID: 84883250657     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100014815     Document Type: Editorial

References (12)

1. Massoud F, Léger G. Pharmacological treatment of Alzheimer disease. Can J Psychiatry. 2011;56(10):579-88.
2. Gauthier S, Patterson C, Chertkow H, et al. 4th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia. Can J Neurol Sci. 2012;39(6 Suppl 5):S1-8.
3. Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev. 2006 (1):CD001190.
4. Birks J, Grimley Evans J, Iakovidou V, Tsolaki M. Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev. 2009 Apr 15; (2):CD001191.
5. Loy C, Schneider L. Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD001747.
6. Saleh S, Kirk A, Morgan DG, Karunanayake C. Less education predicts anticholinesterase discontinuation in dementia patients. Can J Neurol Sci. 2013;40(5):684-90.
7. Amuah JE, Hogan DB, Eliasziw M, et al. Persistence with cholinesterase inhibitor therapy in a population-based cohort of patients with Alzheimer's disease. Pharmacoepidemiol Drug Saf. 2010;19(7):670-9.
8. Herrmann N, Binder C, Dalziel W, Smyth S, Camacho F. Persistence with cholinesterase inhibitor therapy for dementia: an observational administrative health database study. Drugs Aging. 2009;26(5)403-7.
9. Massoud F, Dorais M, Charbonneau C, Lescrauwaet B, Boucher JM, LeLorier J. Drug utilization review of cholinesterase inhibitors in Quebec. Can J Neurol Sci. 2008;35(4):508-9.
10. Gardette V, Andrieu S, Lapeyre-Mestre M, et al. Predictive factors of discontinuation and switch of cholinesterase inhibitors in community-dwelling patients with Alzheimer's disease: a 2-year prospective, multicentre, cohort study. CNS Drugs. 2010;24(5): 431-42.
11. Massoud F, Desmarais JE, Gauthier, S. Switching cholinesterase inhibitors in older adults with dementia. Int Psychogeriatr. 2011; 23(3):372-8.
12. Lopez OL, Becker JT, Wahed AS, et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry. 2009;80(6): 600-7.